Dapagliflozin aids glycemic control in type 2 diabetes

March 20, 2012
Dapagliflozin aids glycemic control in type 2 diabetes

(HealthDay) -- For patients with inadequately controlled type 2 diabetes, treatment with dapagliflozin is associated with improved glycemic control, stabilized insulin dosing, and weight reductions, according to research published in the March 20 issue of the Annals of Internal Medicine.

To evaluate the efficacy and safety of dapagliflozin, John P.H. Wilding, D.M., of University Hospital Aintree in Liverpool, U.K., and associates randomly assigned 800 patients with inadequately controlled , receiving at least 30 units of insulin daily, with or without up to two oral antidiabetic drugs, to receive a daily dose of dapagliflozin (2.5, 5, or 10 mg) or placebo for 48 weeks.

After 24 weeks, the researchers found that patients taking dapagliflozin had a 0.79 to 0.96 percent decrease in mean hemoglobin A1c, compared with a 0.39 percent decrease with placebo. The daily insulin dose decreased by 0.63 units with dapagliflozin compared with an increase of 5.65 units in the . Dapagliflozin was associated with a decrease of 0.92 to 1.61 kg in body weight, compared with an increase of 0.43 kg in the placebo group. At 48 weeks, these effects were maintained. Patients in the pooled dapagliflozin groups had a higher rate of hypoglycemic episodes compared with the placebo group (56.6 versus 51.8 percent).

"Dapagliflozin improves glycemic control, stabilizes insulin dosing, and reduces weight without increasing major in patients with inadequately controlled ," the authors write.

The study was funded by AstraZeneca and Bristol-Myers Squibb, co-developers of dapagliflozin. Several of the authors are employees of AstraZeneca.

Explore further: Study suggests drug significantly improves glycemic control in type one diabetics on insulin

More information: Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

Recommended for you

Do germs cause type 1 diabetes?

May 16, 2016

Germs could play a role in the development of type 1 diabetes by triggering the body's immune system to destroy the cells that produce insulin, new research suggests.

Melatonin signaling is a risk factor for type 2 diabetes

May 12, 2016

A sleeping pancreas releases less insulin, but how much insulin drops each night may differ from person to person, suggests a study published May 12, 2016 in Cell Metabolism. Up to 30 percent of the population may be predisposed ...

New gene for familial high cholesterol

May 12, 2016

New research from Denmark reveals the gene that explains one quarter of all familial hypercholesterolemia with very high blood cholesterol. Familial hypercholesterolemia is the most common genetic disorder leading to premature ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.